Decision to list haemodialysis products supplied by BSN Medical Limited

Hospital devices

Decision

We are pleased to announce the approval of a listing agreement for a range of haemodialysis products with BSN Medical Limited.

In summary this will result in:

  • Listing 10 Haemodialysis procedure packs from BSN Medical in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019 under a national agreement that all DHBs may purchase under (“Agreement”).
  • DHBs continuing to be able to purchase other suppliers’ brands of haemodialysis products.
This Agreement would supersede any existing DHB contracts with this supplier for the devices listed in the Schedule 1 of the Agreement.

Any changes to the original proposal?

This decision was subject to consultation with a letter dated 13 November 2018.

No changes have been made to the proposal following consultation.

Who we think will be most interested

  • DHB staff
    • Haemodialysis staff
    • Procurement Officers
  • Suppliers and Wholesalers

Detail about this decision

In February 2018 PHARMAC issued a Request for Proposals (“RFP”) for haemodialysis products for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation processes and consulting on the provisional Agreement reached with BSN Medical, PHARMAC has decided to list BSN Medical’s range of Propax branded procedure packs in Part III of Section H of the Pharmaceutical Schedule from 1 February 2019.

The list of BSN Medical's products will be available on PHARMAC's website from 1 February 2019, in both a PDF document and an Excel spreadsheet.

DHBs that purchase BSN Medical haemodialysis products must do so under the terms and conditions, and at the prices, included in the Agreements, from 1 February 2019. DHBs can continue to choose which haemodialysis products they purchase.

Our response to what you told us

We appreciate the time people took to respond to this consultation. 

A summary of the main themes raised in feedback and our responses to the feedback received are set out below:

Theme

PHARMAC Staff Comment

Ministry of Health advising no technical resource impacts anticipated as a result of proposals

Noted

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.